Mechanism-based modeling of rebound tachycardia after chronic /- propranolol infusion in spontaneous hypertensive rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 2, 1999, Pages 664-671

  Brynne, Lena ^a,b   Paalzow, Lennart K ^a   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Box 580   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; OROSOMUCOID; PLACEBO; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERANCE; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; HEART RATE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REBOUND; RECEPTOR DENSITY; RECEPTOR UPREGULATION; SENSITIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; TACHYCARDIA;

ADRENERGIC BETA-ANTAGONISTS; ALGORITHMS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EXERTION; HALF-LIFE; HEART RATE; HYPERTENSION; INJECTIONS, SUBCUTANEOUS; MALE; MODELS, BIOLOGICAL; PHYSICAL CONDITIONING, ANIMAL; PROPRANOLOL; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; SUBSTANCE WITHDRAWAL SYNDROME; TACHYCARDIA;

EID: 0032799513     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Aarons RD and Molinoff PB (1982) Changes in the density of beta adrenergic receptors in rat lymphocytes, heart and lung after chronic treatment with propranolol. J Pharmacol Exp Ther 221:439-443.
2. Aarons RD, Nies AS, Gal J and Hegstrand LR (1980) Elevation of β-adrenergic receptor density in human lymphocytes after propranolol administration. J Clin Invest 65:949-957.
3. Bauer JA and Fung H-L (1994) Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm Res 11:816-823.
4. Beal SL and Sheiner LB (1992) NONMEM User's Guides. NONMEM Project Group, University of California at San Francisco, San Francisco, CA.
5. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Biol Sci 220:141-162.
6. Boudoulas H, Lewia RP, Kates RE and Dalamangas G (1977) Hypersensitivity to adrenergic stimulation after propranolol withdrawal in normal subjects. Ann Intern Med 87:433-436.
7. 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol 8:S70-S73.
8. Brown L, Deighton NM, Bals S, Söhlmann W, Zerkowski H-R, Nichel MC and Brodde O-E (1992) Spare receptors for β-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart. J Cardiovasc Pharmacol 19:222-232.
9. Brynne L, Karlsson MO and Paalzow LK (1998) The concentration-effect relationship of l-propranolol and metoprolol in spontaneous hypertensive rats after exercise-induced tachycardia. J Pharmacol Exp Ther 286:1152-1158.
10. Cramb G, Griffiths NM, Aiton JF and Simmons NL (1984) Biochemical and physiological adaptation to chronic propranolol treatment in the rat. Biochem Pharmacol 33:1969-1976.
11. Dayneka NL, Garg V and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
12. De Mey C (1997) Inverse PK/PD: Estimation and differentiation of bioavailability from effect kinetics: Observations with β-adrenoceptor antagonists. Int J Clin Pharmacol Ther 35:453-457.
13. Ebii K, Fukunaga R, Taniguchi T, Fujiwara M, Nakayama S, Saitoh Y and Kimura Y (1991) Effects of chronic administration of carteolol on β-adrenoceptors in spontaneously hypertensive rat heart. Jpn J Pharmacol 56:505-512.
14. Faulkner SL, Hopkins JT, Boerth RC, Young JL, Jellett LB, Nies AS, Bender HW and Shand DG (1973) Time required for complete recovery from chronic propranolol therapy. N Engl J Med 289:607-609.
15. Fitzgerald GA, Robertson D and Wood AJ (1981) Beta-adrenoceptor down-regulation by dynamic exercise and upright posture in man. Trans Assoc Am Physicians 94:310-313.
16. Frishman WH (1987) Beta-adrenergic blocker withdrawal. Am J Cardiol 56:26F-32F.
17. Gaddum JH (1937) The quantitative effects of antagonistic drugs. J Physiol 89:7P-9P.
18. Gȧrdmark M, Brynne L, Hammarlund-Udeneas M and Karlssom MO (1999) Interchangeability and predictive performance of empirical tolerance models. Clin Pharmacokinet 36:145-167.
19. Gibaldi M and Perrier D (1982) In Pharmacokinetics, 2nd ed (Swarbrick J ed) pp 63-65, Marcel Dekker, New York.
20. Houston MC and Hodge R (1988) Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 116:515-523.
21. Imamura H, Maruyama T, Okabe H, Shimada H and Otagiri M (1994) A simple and rapid fluorometric determination method of alpha 1-acid glycoprotein in serum using quinaldine red. Pharm Res 11:566-670.
22. Jonsson EN and Karlsson MO (1998) Xpose: An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comp Methods Prog Med 58:51-64.
23. Lima JJ, Krukemyer JJ and Boudoulas H (1989) Drug- or hormone-induced adaptation: Model of adrenergic hypersensitivity. J Pharmacokinet Biopharm 17:347-364.
24. Lohse MJ (1993) Molecular mechanisms of membrane receptor desensitization. Biochem Biophys Acta 1179:171-188.
25. Maisel AS, Murray D, Lotz M, Rearden A, Irwin M and Michel MC (1991) Propranolol treatment affects parameters of human immunity. Immunopharmacology 22:157-164.
26. Miller RR, Olson HG, Amsterdam EA and Mason DT (1975) Propranolol-withdrawal rebound phenomenon. N Engl J Med 293:416-418.
27. Motulsky HJ and Insel PA (1982) Adrenergic receptors in man: Direct identification, physiologic regulation, and clinical alterations. N Engl J Med 307:18-29.
28. Nattel S, Rangno RE and Van Loon G (1979) Mechanism of propranolol withdrawal phenomena. Circulation 59:1158-1164.
29. Paraskevopoulos JA, Karayannacos PE, Dontas I, Kotsarelis D, Drouva S and Skalkeas G (1991) Mechanism of growth retardation following chronic administration of β-adrenoceptor antagonists to developing rats. J Int Med Res 19:296-304.
30. Prichard BNC, Tomlinson B, Walden RJ and Bhattacharjee P (1983) The β-adrenergic blockade withdrawal phenomenon. J Cardiovasc Pharmacol 5:56-62.
31. Reeves RA, Boer WH, DeLeve L and Leenen FHH (1989) β-Blockade disappearance rate predicts β-adrenergic hypersensitivity. Clin Pharmacol Ther 46:279-290.
32. Rutledge RD and Garrick C (1989) Determination of metoprolol and its α-hydroxide metabolite in serum by reversed-phase high-performance liquid chromatography. J Chromatogr Sci 27:561-565.
33. Sheiner LB, Stanski DR, Vozeh S, Miller RD and Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther 25:358-370.
34. Sheiner LB and Verotta D (1995) Further notes on physiologic indirect response models. Clin Pharmacol Ther 13:238-240.
35. Statistical Science, Inc. (1993) S-PLUS Reference Manual. DataSci, a division of Mathsoft Inc, Version 3.3, Seattle.
36. van den Meiracker AH, Man in't Veld AJ, Boomsma F, Fischberg DJ, Molinoff PB and Schalekamp ADH (1989) Hemodynamic and β-adrenergic receptor adaptations during long-term β-adrenoceptor blockade. Circulation 80:903-914.
37. Walle T, Webb JG, Bagwell EE, Walle UK, Daniell HB and Graffney TE (1988) Stereoselective delivery and actions of beta receptor antagonists. Biochem Pharmacol 37:115-124.
38. Wellstein A, Palm D, Pitschner HF and Beiz GG (1985) Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man. Eur J Pharmacol 29:131-147.
39. Yasuhara M, Firjiwara J, Kitade S, Katayama H, Okumura K and Hori R (1983) Effect of altered plaama protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: Role of alpha-1-acid glycoprotein. J Pharmacol Exp Ther 235:513-520.